Psychomotor performance and fitness to drive: The influence of psychiatric disease and its pharmacological treatment

Psychiatry Research

Volumn 176, Issue 2-3, 2010, Pages 236-241

  De las Cuevas, Carlos ^a,b   Ramallo, Yolanda ^b,c   Sanz, Emilio J ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c Canary Islands Health Service   (Spain)

Author keywords

Driving; Mental illness; Psychotropic drugs

Indexed keywords

ANTICONVULSIVE AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLORAZEPATE; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DRIVING ABILITY; FEMALE; HOSPITAL ADMISSION; HUMAN; LICENCE; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MENTAL DISEASE; MENTAL HEALTH; MOTOR COORDINATION; OUTPATIENT; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA; SCORING SYSTEM; STIMULUS RESPONSE; SUBSTANCE ABUSE; TRAFFIC SAFETY; TREATMENT DURATION; TREATMENT OUTCOME; VELOCITY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ATTENTION; AUTOMOBILE DRIVING; COGNITION; DISCRIMINATION (PSYCHOLOGY); FEMALE; HUMANS; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; MIDDLE AGED; MOTIVATION; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; RESIDENCE CHARACTERISTICS; SPAIN; YOUNG ADULT;

EID: 77949774563     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2009.02.013     Document Type: Article

References (39)

1. Allen D., Curran H.V., Lader M. The effects of repeated doses of clomipramine and alprazolam on physiological, psychomotor and cognitive functions in normal subjects. European Journal of Clinical Pharmacology 1991, 40(4):355-362.
2. Alvarez F.J., Del Rio M.C. Drugs and driving. Lancet 1994, 334:282.
3. Amado-Boccara I., Gougoulis N., Poirier-Littré M.F., Galinowski A., Lôo H. Effects of antidepressants on cognitive functions. Review of the literature. Encephale 1994, 20(1):65-77.
4. Bartfai A., Asberg M., Mårtensson B., Gustavsson P. Memory effects of clomipramine treatment: relationship to CSF monoamine metabolites and drug concentrations in plasma. Biological Psychiatry 1991, 30(11):1075-1092.
5. Beck C.A., Williams J.V., Wang J.L., Kassam A., El-Guebaly N., Currie S.R., Maxwell C.J., Patten S.B. Psychotropic medication use in Canada. Canadian Journal of Psychiatry 2005, 50(10):605-613.
6. Blum D., Meador K., Biton V., Fakhoury T., Shneker B., Chung S., Mills K., Hammer A., Isojärvi J. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 2006, 67(3):400-406.
7. Brunnauer A., Laux G., Geiger E., Möller H.J. The impact of antipsychotics on psychomotor performance with regards to car driving skills. Journal of Clinical Psychopharmacology 2004, 24(2):155-160.
8. Brunnauer A., Laux G., Geiger E., Soyka M., Möller H.J. Antidepressants and driving ability: results from a clinical study. Journal of Clinical Psychiatry 2006, 67(11):1776-1781.
9. de Carvalho S.C., Marcourakis T., Artes R., Gorenstein C. Memory performance in panic disorder patients after chronic use of clomipramine. Journal of Psychopharmacology 2002, 16(3):220-226.
10. De Gier J.J. Medicinal drugs and driving: application of a categorisation system by community pharmacists. Proceedings of the 15th International Conference on Alcohol, Drugs and Traffic Safety 2000.
11. De las Cuevas C., Sanz E.J. Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry 2004, 4:18.
12. De las Cuevas C., Sanz E.J. Polypsychopharmacy. A frequent and debatable practice in psychiatric inpatients. Journal of Clinical Psychopharmacology 2005, 25(5):510-512.
13. De las Cuevas C., Sanz E.J., De la Fuente J., Cabrera C., Mateos A. Prescribed daily doses and "risk factors" associated with the use of benzodiazepines in primary care. Pharmacoepidemiology and Drug Safety 1999, 8(3):207-216.
14. Department of the Environment, Transport and the Regions (DETR) Antidepressants and Road Safety: a Literature Review and Commentary (Report No.18). United Kingdom 2003.
15. Eelkena R.C., Brosseau J., Koshnick R., McGee C. A statistical study on the relationship between mental illness and traffic accidents-a pilot study. American Journal of Public Health 1970, 60:459-469.
16. Fairweather D.B., Hindmarch I. The behavioural toxicity of reversible inhibitors of monoamine oxidase A: laboratory and clinical investigations. Journal of Clinical Psychopharmacology 1995, 15(4, Suppl. 2):68S-75S.
17. Galski T., Ehle H.T., Bruno R.L. An assessment of measures to predict the outcome of driving evaluations in patients with cerebral damage. American Journal of Occupational Therapy 1990, 44:709-713.
18. Goldney R., Bain M. Prevalence of psychotropic use in a South Australian population. Australasian Psychiatry 2006, 14(4):379-383.
19. Gombao J.C., Muñoz A., Monterde H. El Reconocimiento Psicológico Oficial para la Licencia de Armas y Carnet de Conducir con el Equipo LND. LNDETER SA, Madrid 1999.
20. Grabe H.J., Wolf T., Grätz S., Laux G. The influence of polypharmacological antidepressive treatment on central nervous information processing of depressed patients: implications for fitness to drive. Neuropsychobiology 1998, 37(4):200-204.
21. Grabe H.J., Wolf T., Grätz S., Laux G. The influence of clozapine and typical neuroleptics on information processing of the central nervous system under clinical conditions in schizophrenic disorders: implications for fitness to drive. Neuropsychobiology 1999, 40(4):196-201.
22. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology 1976, National Institute of Mental Health, Bethesda.
23. Hale A.S. The importance of accidents in evaluating the cost of SSRIs: a review. International Clinical Psychopharmacology 1994, 9:195-201.
24. Harris M.C. Psychotropic medication and driving. Psychiatry in Practice 1997, 16:5-7.
25. Harris M. Psychiatric conditions with relevance to fitness to drive. Advances in Psychiatric Treatment 2000, 6:261-269.
26. Havard J.D.J. Medical Aspects of Fitness to Drive: Medical Commission on Accident Prevention 1976, 43-52. HMSO, London. 3rd ed.
27. Kerr J.S., Hindmarch I. Accidents and Antidepressants. Geriatric Medicine 1995, July, 29-31.
28. Korteling J.E., Kaptein N.A. Neuropsychological driving fitness tests for brain-damaged subjects. Archives of Physical Medicine and Rehabilitation 1996, 77:138-146.
29. Metzner J.L., Dentino A.N., Godard S.L. Impairment in driving and psychiatric illness. Journal of Neuropsychiatry and Clinical Neurosciences 1993, 5:211-220.
30. Monterde H. Evaluación en Tráfico y Seguridad Vial, in Manual de Evaluación Psicológica 1997, Fundamentos, Madrid, Siglo XXI, Técnicas y Aplicaciones.
31. Montoro L., Mirabet E. The Spanish medical and psychotecnical exam model within the context of second directive (91/439/EEC). Results when conducted on a specific group of drivers (45-70 age range). Revista Española de Salud Pública 2003, 77:151-160.
32. Odell M. Assessing fitness to drive: part 2. Australian Family Physician 2005, 34(6):475-477.
33. Official Journal of the European Union (OJEU) Council directive 91/439/EEC of 29 July 1991 on driving licences. Official Journal L 1991, 237:1-24. 24/08/1991.
34. Ohayon M.M., Lader M.H. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. Journal of Clinical Psychiatry 2002, 63(9):817-825.
35. Seppala T., Linnoila M., Mattila M.J. Drugs, alcohol and driving. Drugs 1979, 17:389-408.
36. Soyka M., Winter C., Kagerer S., Brunnauer M., Laux G., Möller H.J. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. Journal of Psychiatric Research 2005, 39(1):101-108.
37. Tunbridge R.J., Rowe D.J., Keigan M., Jackson P.G. The incidence of drugs in road accident fatalities in Great Britain. Proceedings of the 15th International Conference on Alcohol, Drugs and Traffic Safety 2000.
38. World Health Organization The ICD-10 classification of mental and behavioural disorders. Clinical Descriptions and Diagnostic Guidelines. WHO, Geneva 1992.
39. Wylie K.R., Thompson D.J., Wildgust H.J. Effects of depot neuroleptics on driving performance in chronic schizophrenic patients. Journal of Neurology, Neurosurgery & Psychiatry 1993, 56:910-913.